BioWorld

July 11, 2005

View Archived Issues

Sonus, FDA Agree To Terms For Tocosol Paclitaxel SPA

Sonus Pharmaceuticals Inc. is moving forward with pivotal development plans for its lead product, Tocosol Paclitaxel, after completing a special protocol assessment for a single Phase III trial. (BioWorld Today) Read More

Panacea Pharmaceuticals' Series C Round Gets $7M

Read More

Money, Experience Drawing Foreign Companies To U.S.

Read More

Conforma Gains Synthetic Anthracycline From Japan

Read More

Other News To Note

Read More